← All news

FROM THE NEWS FEED

Compass Pathways’ New 52-Week Topline Open-Label Data from Phase 3 COMP005 Trial Demonstrates Additional Benefit from Another COMP360 Dose in Part C Extending Durability Out to 1 Year

2026-09-09 • Psychedelic Invest

Article summary

LONDON & NEW YORK, September 09, 2026--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today…

Continue to the original publication for the complete article.